B0383 - The Impact of Treatment Switch Among Prevalent Patients With Crohn’s Disease Treated With a First-Line Biologic: A U.S. Retrospective Claims Database Study

Patrick Gagnon-Sanschagrin, MSc¹, Myrlene Sanon, MPH², Mikhaïl Davidson, BSc³, Annie Guérin, MS³, Cynthia Willey, MSPH, PhD⁴, Sumesh Kachroo, PhD⁵, Timothy Hoops, PhD², Dominik Naessens, PhD, MBA⁶, Martin Cloutier, BSc, MSc^1
1Analysis Group, Montreal, PQ, Canada; ²Janssen Global Services LLC, Horsham, PA; ³Analysis Group Inc., Montreal, PQ, Canada; ⁴University of Rhode Island, Kingston, RI; ⁵Janssen Scientific Affairs, LLC, Horsham, PA; ⁶Janssen Pharmaceutica NV, Beerse, Antwerpen, Belgium

Introduction: Treatment switching often occurs with biologic use among patients with Crohn’s disease (CD) and has been associated with worsened clinical symptoms and functional impairment. However, little is known about its impact on healthcare resource utilization (HRU) and costs. This study assessed the economic burden associated with treatment switching among adults with CD in the United States (US).

Methods: Data from the IBM® MarketScan® Commercial Subset (10/01/2015-03/31/2020) were used to identify adult patients newly diagnosed with CD (at least 2 CD diagnoses at least 30 days apart) and that were treated with a first line biologic (prescription fill/injection) on or after their CD diagnosis. The index date was defined as the date of the first line biologic. Patients were classified into the switchers or non-switchers cohort based on whether or not they switched to another biologic or 5-aminosalicylic acid or immunomodulator during the 12-month study period after the index date. Mean time to treatment switch was estimated using Kaplan-Meier analyses. All-cause HRU and healthcare costs (2020 USD) during the study period were described and compared (unadjusted) overall and for the 2 cohorts.

Results: Among 4,006 patients included in the study, 640 were switchers and 3,366 were non-switchers. Overall, mean age was 39.5 years and 50.9% were female. Rates of treatment switch were 7.1% at 6 months and 16.0% at 12 months (Figure). Additionally, rates of prolonged corticosteroid use (at least 90 days) was higher in switchers compared to non-switchers (31.6% vs 8.2%; p< 0.01). Switchers also had higher rates of inpatient admissions (25.9% vs 12.6%; p< 0.01), emergency department visits (41.6% vs 35.4%; p< 0.01), and number of outpatient visits (22.8 vs 17.0; p< 0.01) compared to non-switchers (Table). Similarly to HRU, total all-cause healthcare costs were higher among switchers than non-switchers ($95,689 vs $81,027; p< 0.01), which was mainly driven by higher medical costs ($24,135 vs $14,416; p< 0.01; Table). Among age groups, switchers 30-39 years incurred the highest total cost ($100,676 vs 78,265, p< 0.01).

Discussion: In this real-world study, patients with CD who switched biologic treatments, which is a marker of inadequate treatment, incurred significantly higher HRU and healthcare costs. These findings suggest a potential unmet need with current treatment options and highlight the impact of switching biologics on the economic burden of patients with CD.




Disclosures:


Patrick Gagnon-Sanschagrin, MSc¹, Myrlene Sanon, MPH², Mikhaïl Davidson, BSc³, Annie Guérin, MS³, Cynthia Willey, MSPH, PhD⁴, Sumesh Kachroo, PhD⁵, Timothy Hoops, PhD², Dominik Naessens, PhD, MBA⁶, Martin Cloutier, BSc, MSc¹. B0383 - The Impact of Treatment Switch Among Prevalent Patients With Crohn’s Disease Treated With a First-Line Biologic: A U.S. Retrospective Claims Database Study, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.